KNTE - Kinnate Biopharma Inc. Stock Price, Fair Value and News

$2.65

Market Closed

KNTE Stock Valuation Analysis

Valuation

Max Portfolio %

KNTE Price Action

KNTE RSI Chart

KNTE Stock Valuation Analysis

Valuation

Max Portfolio %

KNTE Valuation

KNTE Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KNTE Fundamentals

KNTE Earnings

KNTE Profitability

KNTE Investor Care

Revenue & Growth

About Kinnate Biopharma Inc.

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

CEO	Mr. Nima Farzan M.B.A.
WEBSITE	kinnate.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	84